Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $28.2 million.

  • Apellis Pharmaceuticals' Share-based Compensation rose 2.59% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year decrease of 4.35%. This contributed to the annual value of $114.1 million for FY2024, which is 7.72% up from last year.
  • Apellis Pharmaceuticals' Share-based Compensation amounted to $28.2 million in Q3 2025, which was up 3.64% from $27.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Share-based Compensation ranged from a high of $30.3 million in Q1 2024 and a low of $16.4 million during Q1 2021.
  • In the last 3 years, Apellis Pharmaceuticals' Share-based Compensation had a median value of $27.5 million in 2024 and averaged $27.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 76.88% in 2021, then declined by 9.80% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Share-based Compensation stood at $19.3 million in 2021, then increased by 25.52% to $24.2 million in 2022, then rose by 8.16% to $26.2 million in 2023, then rose by 0.36% to $26.3 million in 2024, then increased by 2.59% to $28.2 million in 2025.
  • Its last three reported values are $28.2 million in Q3 2025, $27.2 million for Q2 2025, and $27.4 million during Q1 2025.